OPT Opthea Limited ADRs

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$9.61  -0.39 (-3.90%)
As of 03/04/2021 13:38:47 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
ADRs
Small cap
Health Care
Biotechnology
Australia

04/12/2012
42,208,021
23,017
$422,080,210
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
6.51
7,435.37
0.00%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy